Secondary Logo

Journal Logo

New Drugs 2019, part 4

doi: 10.1097/01.NURSE.0000611472.27241.72
CE Connection
Free

For more than 72 additional continuing-education articles related to pharmacology topics, go to NursingCenter.com/CE.

Earn CE credit online: Go to www.nursingcenter.com/CE/nursing and receive a certificate within minutes.

Nursing2019 will no longer facilitate mail-in continuing-education tests. All CE tests must be taken online at www.nursingcenter.com/ce/nursing. Please address any questions to customer service at 1-800-787-8985.

Back to Top | Article Outline

INSTRUCTIONS New Drugs 2019, part 4

TEST INSTRUCTIONS

  • Read the article. The test for this CE activity is to be taken online at www.nursingcenter.com/CE/nursing.
  • You'll need to create (it's free!) and log in to your personal CE Planner account before taking online tests. Your planner will keep track of all your Lippincott Professional Development online CE activities for you.
  • There's only one correct answer for each question. A passing score for this test is 13 correct answers. If you pass, you can print your certificate of earned contact hours and access the answer key. If you fail, you have the option of taking the test again at no additional cost.
  • For questions, contact Lippincott Professional Development: 1-800-787-8985.
  • Registration deadline is September 3, 2021.
Back to Top | Article Outline

PROVIDER ACCREDITATION

Lippincott Professional Development will award 1.5 contact hours and 1.5 pharmacology credits for this continuing nursing education activity. Lippincott Professional Development is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation. This activity is also provider approved by the California Board of Registered Nursing, Provider Number CEP 11749 for 1.5 contact hours, and the District of Columbia, Georgia, and Florida CE Broker #50-1223.

Payment: The registration fee for this test is $17.95.

New Drugs 2019, part 4

GENERAL PURPOSE: To review nine drugs recently approved by the FDA. LEARNING OBJECTIVES/OUTCOMES: After completing this continuing-education activity, you should be able to: 1. Discuss indications for each drug discussed. 2. List adverse reactions for each drug discussed. 3. List nursing considerations for each drug discussed.

  1. Which statement is correct about fostamatinib?
    1. It reduces antibody-mediated destruction of platelets.
    2. It is indicated as an initial treatment for ITP.
    3. It enhances activity of SYK.
  2. Treatment with fostamatinib should be reduced, interrupted, or discontinued if
    1. the patient develops severe diarrhea.
    2. the patient's platelet count increases during the first month of treatment.
    3. liver enzyme levels drop significantly.
  3. A significant adverse reaction to TPO receptor agonists is
    1. thromboembolic events.
    2. cardiac dysrhythmias.
    3. tinnitus.
  4. Which dosage of avatrombopag is recommended for patients with chronic ITP?
    1. 20 mg/day
    2. 40 mg/day
    3. 60 mg/day
  5. Which drug is approved only to treat thrombocytopenia in adults with CLD scheduled to undergo a procedure?
    1. fostamatinib
    2. avatrombopag
    3. lusutrombopag
  6. An adverse reaction to lusutrombopag is
    1. abnormal bleeding.
    2. hypertension.
    3. headache.
  7. In patients with hATTR, abnormal amyloid protein deposits most often occur in the
    1. eyes.
    2. peripheral nervous system.
    3. liver.
  8. Which statement is true concerning IRRs associated with patisiran?
    1. The frequency of IRRs increases with continued treatment.
    2. Patients in the clinical trials were premedicated to prevent IRRs.
    3. Many patients experience IRRs that require infusion interruption.
  9. Teach patients taking patisiran about the risk of
    1. orthostatic hypotension.
    2. abnormal bleeding.
    3. ocular adverse reactions.
  10. In clinical trials, inotersen
    1. increased platelet counts.
    2. reduced neuropathy.
    3. increased serum TTR protein levels.
  11. Compared with ivermectin, moxidectin
    1. is significantly better at suppressing microfilariae in the skin.
    2. has a shorter duration of action.
    3. can kill adult forms of the O. volvulus parasite.
  12. Which statement is correct about moxidectin?
    1. It must be taken with a full meal.
    2. It is likely to cause significant pruritus during the first week of treatment.
    3. Hypertension is a common adverse reaction.
  13. The first drug approved to reverse the anticoagulant effects of rivaroxaban is
    1. idarucizumab.
    2. apixaban.
    3. andexanet alfa.
  14. Which statement is accurate concerning the boxed warning for andexanet alfa?
    1. The risk of death following treatment is greatest after 30 days.
    2. Underlying disease predisposes patients to thromboembolic events.
    3. Reversing the drug's anticoagulant effect caused thrombotic events in healthy volunteers.
  15. Which statement is correct about plazomicin?
    1. It is a primary treatment for cUTI.
    2. It is less likely than most aminoglycosides to cause ototoxicity.
    3. It should be reserved for patients who have limited treatment options.
  16. For patients taking plazomicin, which lab value should be monitored daily?
    1. creatinine clearance
    2. platelet count
    3. red blood cell count
  17. Which statement about eravacycline is correct?
    1. It is administered orally.
    2. In clinical trials, it was more effective than ertapenem and meropenem.
    3. Its only approved indication is to treat cIAIs.
  18. During clinical trials, the most common reason for discontinuing eravacycline therapy was
    1. photosensitivity.
    2. GI upset.
    3. tooth discoloration.
Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.